An observational study in Cardiogenic Shock, Heart Failure and Acute Decompensated Heart Failure (ADHF), sponsored by Abiomed Inc.. Active, not recruiting at 24 sites in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Abiomed Inc. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Shock, Cardiogenic with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Shock, Cardiogenic · United States.
Among the 50 studies in Shock, Cardiogenic with a site in United States, this one is the 15th largest by planned enrollment of the 25 observational ones that give a count, is one of 6 that started in 2024, is one of 25 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 50th registered.
296 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →19 of the 50 studies in Shock, Cardiogenic with a site in United States are open now. Recruiting first, the newest first:
Abiomed Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18+
Thomas Jefferson University · Sites in United States
Ages 18+
Atlantic Health System · Sites in United States
Ages 18–100
Abiomed Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 1 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 200 across 155 observational studies indexed under Shock, Cardiogenic.
Median enrollment 30 across the 25 interventional studies, 124 across the 25 observational. Of the 20 that completed or were terminated, 6 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Abiomed Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Abiomed Inc. is the lead sponsor of 34 studies on the registry; 5 are open to participants now.
Johnson & Johnson has 7 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock, Cardiogenic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05267886Ottawa Heart Institute Research CorporationCAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock | 2026-12 |
| NCT05800951Henry Ford Health SystemCan Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock | 2026-12-31 |
| NCT06253104Tufts Medical CenterChanges in Skeletal Muscle Thickness in Patients With Acute Heart Failure | 2026-12-31 |
| NCT07402018Thomas Jefferson UniversityIntra-aortic Balloon Counterpulsation (IABC) Compliance | 2026-12-31 |
| NCT07825363NIRSense Inc.Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 50 studies in Shock, Cardiogenic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This post-approval study will evaluate the real-world safety and effectiveness of the Impella CP with SmartAssist and Impella 5.5 with SmartAssist heart pumps in pediatric patients with cardiogenic shock or severe heart failure requiring temporary mechanical circulatory support.
The study will collect data from children and young adults younger than 22 years of age who receive an Impella device as part of their routine clinical care at hospitals participating in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry.
The primary objective is to assess survival at the time the Impella device is removed. Information collected during the patient's hospitalization, including clinical outcomes and adverse events, will be used to further evaluate the performance of these commercially approved devices in the pediatric population.
Cardiogenic shock and severe heart failure are associated with substantial morbidity and mortality in pediatric patients. Timely restoration of adequate circulation is critical to maintain organ perfusion, support recovery of cardiac function, and facilitate transition to advanced therapies when needed.
Pediatric patients often face unique challenges related to disease complexity, body size, and limitations in available treatment options. The Impella family of left ventricular support devices provides temporary mechanical circulatory support by unloading the ventricle and increasing cardiac output, and has been used in pediatric patients with cardiogenic shock and advanced heart failure. Published reports and analyses of real-world clinical experience suggest that Impella support may provide effective short-term hemodynamic stabilization and serve as a bridge to myocardial recovery, durable mechanical support, heart transplantation, or re-transplantation.
This post-approval study is being conducted to further evaluate the continued safety and effectiveness of the Impella CP with SmartAssist and Impella 5.5 with SmartAssist devices in pediatric patients receiving temporary left ventricular mechanical circulatory support. The study leverages data collected through the Advanced Cardiac Therapies Improving Outcomes Network (ACTION), a multicenter registry that captures real-world clinical information on pediatric patients with heart failure and advanced cardiac therapies.
Clinical, procedural, and outcome data collected during routine care will be analyzed to characterize patient outcomes associated with Impella support in contemporary clinical practice. Information obtained through the study will contribute to the understanding of device performance, safety events, and clinical outcomes in pediatric patients treated with commercially available Impella devices. The results are intended to support ongoing evaluation of these devices in the pediatric population and to provide additional real-world evidence regarding their use in patients requiring temporary hemodynamic support.
Pediatric patients (\< 22 years old) who receive left ventricular hemodynamic support with a left/systemic ventricular Impella device (Impella CPSA or 5.5).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Age ≥ 22 years
Pediatric patients younger than 22 years of age who receive a commercially approved left ventricular Impella device (Impella CP with SmartAssist and/or Impella 5.5 with SmartAssist) as part of routine clinical care and are enrolled through the ACTION (Advanced Cardiac Therapies Improving Outcomes Network) registry.
Device: Impella CP with SmartAssist · Device: Impella 5.5 with SmartAssist
Commercially approved temporary left ventricular support device used to provide hemodynamic support in patients requiring mechanical circulatory support.
Also known as: Impella Device, Impella Left Ventricular Support Systems
Commercially approved temporary left ventricular support device used to provide hemodynamic support in patients requiring mechanical circulatory support.
Also known as: Impella Device, Impella Left Ventricular Support Systems
Survival rate at Impella Device Explant
The primary endpoint is to evaluate the survival rate at Impella device explant. Impella device explant due to unacceptable prognosis will not count towards successful survival to explant.
Time frame: From date of Impella implant until Impella device explant or date of death from any cause, whichever is first. The duration of time allotted until explant is not pre-specified in the study protocol but is estimated up to 12 months
Plan to share: No — Data is simply provided to FDA and intent to publish is not yet determined by Sponsor.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
Of 84 observational studies under Shock, Cardiogenic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.